Suggested Reading

Del Rosso JQ, Thiboutot D, Gallo R, et al. (2013). Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 1: a status report on the disease state, general measures, and adjunctive skin care. Cutis, 92(5): 234-240.

Del Rosso JQ, Thiboutot D, Gallo R, et al. (2013). Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents Cutis, 92(6): 277-284.

Del Rosso JQ, Thiboutot D, Gallo R, et al. (2014). Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 3: a status report on systemic therapies. Cutis, 93(1): 18-28.

Del Rosso JQ, Thiboutot D, Gallo R, et al. (2014). Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea. Cutis, 93(3): 134-138.

Elewski BE, Draelos Z, Dréno B, et al. (2011). Rosacea—global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. J Eur Acad Dermatol Venereol, 25(2): 188-200.

Fowler J, Jarratt M, Moore A, et al. (2012). Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicenter, randomized and vehicle-controlled studies. Br J Dermatol, 166: 633-641.

Fowler J Jr, Jackson M, Moore A, et al. (2013). Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol, 12(6): 650-656.

Stein L, Kircik L, Fowler J, et al. (2014). Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Derm, 13(3): 316-323.

Taieb A, Ortonne JP, Ruzicka T, et al. (2015). Superiority of ivermectin 1% cream over metronidazole 0·75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol, 172(4): 1103-10. doi: 10.1111/bjd.13408.

Tanghetti E, Del Rosso JQ, Thiboutot D, et al. (2014). Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 4: a status report on physical modalities and devices. Cutis, 93(2): 71-76.

Weinstock LB, Steinhoff M. (2013). Rosacea and small intestinal bacterial overgrowth: prevalence and response to rifaximin. JAAD, 68: 875-876.